InvestorsHub Logo
Followers 18
Posts 1646
Boards Moderated 0
Alias Born 06/26/2014

Re: None

Wednesday, 05/26/2021 7:15:21 AM

Wednesday, May 26, 2021 7:15:21 AM

Post# of 448
Nabriva Therapeutics Phase 3 Trial of Antibiotic Medication for Bacterial Pneumonia Meets Primary Endpoint
2021-05-26 07:11:52 AM ET (MT Newswires)
07:11 AM EDT, 05/26/2021 (MT Newswires) -- Nabriva Therapeutics AG (NBRV) said Tuesday that the phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia has achieved its primary endpoint.

The topline results showed that lefamulin was non-inferior to moxifloxacin, with the former demonstrating a critical response success rate of 76.8% compared with 71.4% for moxifloxacin. Lefamulin, a pleuromutilin antibiotic, was also found to be generally safe and well-tolerated, with an overall rate of treatment-emergent adverse events comparable to that of moxifloxacin.

The biopharmaceutical company also said that research partner Sinovant Sciences signed a deal with Sumitomo Pharmaceuticals (Suzhou) Co. Ltd. for development and commercialization rights for lefamulin in Greater China. The deal is expected to close in calendar Q2.

Shares of Nabriva are up about 50% ahead of Wednesday's opening bell.

I use both Fundamental and Technical Analysis.
Opinions posted by me are just that, my opinion.
Buy/sell any type of financial security is the sole
decision of the individual. Make your own sound
judgement or consult a professional licensed